赛科希德(688338) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2024 was ¥75,818,644.14, representing a year-on-year increase of 13.56%[5] - The net profit attributable to shareholders for the same period was ¥30,429,780.54, reflecting a growth of 14.48% compared to the previous year[5] - The net profit after deducting non-recurring gains and losses was ¥30,265,269.59, which is an increase of 14.23% year-on-year[5] - Basic and diluted earnings per share were both ¥0.29, marking a 16.00% increase[5] - Operating profit for Q1 2024 was ¥35,609,570.89, representing a growth of 13.5% from ¥31,347,605.36 in Q1 2023[18] - Net profit for Q1 2024 was ¥30,416,910.80, up 14.0% from ¥26,579,755.16 in Q1 2023[18] - The company's operating profit for Q1 2024 was CNY 38,439,601.69, up 23.2% from CNY 31,189,388.40 in Q1 2023[26] Cash Flow - The net cash flow from operating activities was ¥19,814,813.86, showing a slight increase of 1.69%[5] - Cash flow from operating activities for Q1 2024 was ¥19,814,813.86, slightly up from ¥19,485,555.33 in Q1 2023[20] - In Q1 2024, the net cash flow from operating activities was CNY 19,887,136.35, a slight increase from CNY 19,541,090.62 in Q1 2023, reflecting a year-over-year growth of 1.77%[28] - Total cash inflow from operating activities was CNY 86,495,705.79, down from CNY 91,404,385.93 in the same period last year, indicating a decrease of 5.5%[28] - Cash outflow for operating activities totaled CNY 66,608,569.44, compared to CNY 71,863,295.31 in Q1 2023, representing a reduction of 7.3%[28] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,722,952,464.70, up 0.98% from the end of the previous year[6] - The equity attributable to shareholders was ¥1,630,677,661.33, which increased by 1.90% compared to the previous year[6] - The company reported a total asset of CNY 1,722,952,464.70 as of March 31, 2024, compared to CNY 1,706,235,918.32 at the end of December 2023, reflecting a slight increase[12] - The total current liabilities decreased to CNY 90,641,653.58 from CNY 104,279,368.99, indicating improved liquidity management[14] - The company's total liabilities decreased to CNY 60,225,603.95 from CNY 67,321,680.99 at the end of 2023, indicating a reduction of approximately 10.5%[24] Research and Development - Research and development expenses totaled ¥4,695,066.54, accounting for 6.19% of operating revenue, an increase of 0.48 percentage points[6] - Research and development expenses increased to ¥4,695,066.54 in Q1 2024, up 23.1% from ¥3,811,618.10 in Q1 2023[17] - Research and development expenses for Q1 2024 were CNY 4,695,066.54, an increase of 23.1% compared to CNY 3,811,618.10 in Q1 2023[25] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 6,077[9] - The total equity increased to CNY 1,633,540,597.18 as of March 31, 2024, compared to CNY 1,600,985,076.11 at the end of 2023, marking a growth of 2.0%[24] Inventory and Receivables - The company’s inventory decreased slightly to CNY 48,239,801.98 from CNY 49,790,881.02, suggesting effective inventory management[13] - The company’s accounts receivable increased to CNY 36,145,769.09 from CNY 31,776,284.12, indicating a growth in sales or credit terms[12] - The company's accounts receivable rose to CNY 36,145,769.09 from CNY 31,776,284.12, reflecting a growth of 13.3%[22] Foreign Exchange Impact - The company experienced a foreign exchange gain of ¥139,352.89 in Q1 2024, contrasting with a loss of ¥976,767.08 in Q1 2023[21] - The company experienced a positive impact of CNY 139,352.89 from foreign exchange fluctuations on cash and cash equivalents, contrasting with a negative impact of CNY 976,767.08 in Q1 2023[28] Fixed Assets and Depreciation - The company completed the construction acceptance of its thrombus and hemostatic product project on January 10, 2024, with a fixed asset transfer value of CNY 28,504.99 million[11] - The company expects an annual depreciation expense of CNY 736.63 million for the newly transferred fixed assets[11]